Topic for January 2022
Understanding cervical cancer and papillomaviruses through long-read sequencing.
The CGC webinar series is back after a short break for the holiday season! This January, the CGC Webinar Series featured a talk by Dr. Michael Dean and Ms. Nicole Rossi from the Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics at the National Cancer Institute, NCI in Rockville, Maryland, USA. Dr. Dean is a senior investigator and is interested in inherited (germline) genetic variation, somatic mutations in tumors, and their effects on cancer risk, progression, and response to therapy. His lab, where Ms. Nicole Rossi is a postbac at, has a major focus on human papillomavirus (HPV) and cervical cancer and cancer health disparities in the U.S. and in Latin America.
During the webinar, Dr. Dean and Ms. Rossi will present on their work detecting the integration of HPV in the human genome through the use of long-sequencing reads. To characterize the most carcinogenic HPV, they sequenced 65 fresh-frozen HPV16-driven cervical cancer tumors, with episomal only (EP) or episomal and integrated (EP/INT) phenotypes. They identified monomer episomes as well as switches, deletions and rearrangements. Dr. Dean and his lab used the CGC platform and tools to perform bioinformatic analysis on their sequencing data. To learn more about their research and how they used the CGC, register for the webinar using the button below.
More about the speakers
Dr. Michael Dean is a senior investigator in the Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics at the National Cancer Institute. Dr. Dean is interested in inherited (germline) genetic variation, somatic mutations in tumors, and their effects on cancer risk, progression, and response to therapy. The lab has a major focus on human papillomavirus (HPV and cervical cancer and cancer health disparities in the U.S. and in Latin America.
Ms. Nicole Marie Rossi is a Post-Bacc fellow in the Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics at the National Cancer Institute, NCI in Rockville, Maryland, USA. She earned her Honors Bachelor of Science Degree in biological sciences from the University of Delaware. As an undergraduate, she worked in Dr. Melinda K Duncan’s lab, studying the role of Lactase-Like (LCTL) gene in lens cell homeostasis and cataract formation.
More about us and the CGC
Seven Bridges is the leading biomedical data company, specializing in software and data analytics to drive public and private healthcare research. We deliver end-to-end bioinformatic solutions — including access to datasets, analytic workflows and algorithms, cloud-computing infrastructure, and scientific support — that speed the path from raw experimental data to new treatments and diagnostics.
The Cancer Genomics Cloud (CGC), powered by Seven Bridges and funded by the National Cancer Institute, is a flexible cloud resource platform that enables storage, analysis, and computation of large cancer datasets in the cloud. Since its launch in 2016, the platform has been continuously iterated with new applications and features to address the exponential growth and diversity of complex datasets. With the CGC, any user with an account can easily access petabytes of data, share it, analyze and use the computational power of the cloud without having to learn how to program and get familiar with several different data portals.